- Quebec-based CDL
Laboratories will now offer the validated ClarityDX Prostate risk
score to healthcare providers and their patients suspected of
having aggressive prostate cancer.
- ClarityDX Prostate combines biological and clinical information
using AI-powered learning to generate a risk score for aggressive
prostate cancer.
EDMONTON, AB, May 22, 2024
/CNW/ - Nanostics Inc., a precision health company developing
diagnostic tests with its ClarityDX® platform technology, signed an
agreement with Quebec-based CDL
Laboratories (CDL) to expand access to the ClarityDX Prostate® to
men and their healthcare providers.
ClarityDX Prostate uses biological data, clinical information,
and AI-powered learning models to generate a risk score for
aggressive prostate cancer, marking a significant advancement in
prostate cancer screening. It provides critical support to men and
their healthcare providers in making more informed decisions about
whether to proceed with a biopsy or not following a high
prostate-specific antigen (PSA) test result.
"We are very excited to partner with CDL Laboratories and expand
access to ClarityDX Prostate in Canada", said Dr. John
Lewis, CEO of Nanostics and Bird Dogs Chair of Translational
Oncology at the University of Alberta.
"The risk score provides accurate information to both men and their
doctors regarding the patient's risk of aggressive prostate cancer.
This helps making informed treatment decisions, which are crucial
for enhancing patient outcomes and quality of life".
"At CDL Laboratories, innovation, quality, and excellence are
fundamental. As we leverage cutting-edge AI technology to shape the
future of healthcare, we proudly introduce ClarityDX Prostate
exclusively in Quebec. This
groundbreaking advancement in men's health will empower our 3,500
healthcare professionals and will provide reassurance to tens of
thousands of patients every year", says Laurent Amram, President and Founder of CDL
Laboratories, an ELNA Medical Group company.
ClarityDX Prostate is available in Canada through Nanostics CPSA accredited lab
in Edmonton, Alberta, and has been
used by many male patients in Alberta. For more information or to order
please visit nanosticsdx.com or cdllaboratories.com.
About CDL Laboratories
Established in 1993, CDL Laboratories is a leading provider of
diagnostic laboratory services in Quebec. At the forefront of the medical
testing industry, its mission is fueled by a commitment to
integrating the most advanced diagnostic equipment and
state-of-the-art technologies to deliver precise results in
industry-leading turn-around times. An innovator in the Canadian
healthcare landscape, CDL Laboratories bolsters an unwavering
dedication to the highest quality and excellence with over
1.4M tests per year. It is the most
accredited laboratory in the province and a Roche Diagnostics
showcase for over 25 years. CDL Laboratories is a subsidiary of the
ELNA Medical Group, Canada's
largest integrated network of medical clinics and diagnostic
services.
About Nanostics
Inc.
Nanostics is a private Canadian company that develops and
commercializes novel and noninvasive diagnostic tests. Its core
technology, ClarityDX®, uses advanced machine learning algorithms
to create a disease risk score. ClarityDX is applicable to a wide
range of cancers and other diseases. Nanostics' lead product,
ClarityDX Prostate®, is a test that improves the accuracy of
detecting clinically significant prostate cancer. Read more at:
www.nanosticsdx.com. Follow Nanostics on LinkedIn, YouTube,
Facebook, and Instagram.
SOURCE Nanostics